MedTrace Logo

Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's Disease

NCT03624842 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2018-08-10

No results posted yet for this study

Summary

To afford urgent access to a potential-disease modifying treatment, Dr. Diana Kerwin, in partnership with CTD Holdings, the manufacturer of Trappsol (R) Cyclo(TM), will administer the product to a patient with Alzheimer's Disease who has no other disease-modifying treatment options.

Conditions

  • Late Onset Alzheimer Disease

Interventions

DRUG

Trappsol (R) Cyclo (TM)

Sponsors & Collaborators

  • Kerwin Research Center, LLC

    collaborator OTHER

  • Cyclo Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Diana R Kerwin, MD · Kerwin Research Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03624842 on ClinicalTrials.gov